A+ Blood and Plasma

The U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of Walter Reed Army Institute of Research (WRAIR) intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with Valley Biomedical, INC, 121 Industrial Drive, Winchester, VA 22602 for the procurement of fresh Human human A+ RBCs and plasma in citrate-phosphate-dextrose (CPD). Specifically, the government will establish a Firm Fixed Price contract to purchase the following items:

CLIN 0001 - Human A+ Red Blood Cells/ CPD -- Drug Free -- Qty 130 each
CLIN 0002 - Human A+ Plasma/ CPD -- Drug Free - Qty 104 each
CLIN 0003 - Shipping - Qty 26 each

CLIN 0004 - Optional Surge Human A+ Red Blood Cells/ CPD -- Drug Free - Qty 100 each
CLIN 0005 - Optional Surge Human A+ Plasma/ CPD -- Drug Free - Qty 100 each
CLIN 0006 - Optional Surge Shipping - Qty 4 each

This requirement is for fresh human A+ RBCs and plasma in CPD, collected from a donor pool whose blood products have been tested and found to support the in vitro culturing of Plasmodium falciparum isolates used in the Experimental Therapeutics (WRAIR) anti‐malarial drug screen.

WRAIR has previously purchased blood from Valley Biomedical, Inc. Valley Biomedical is the only vendor that has tested their fresh human A+ RBCs and plasma in CPD with the WRAIR Malaria Research Laboratory parasite strains, and no other company has used WRAIR's parasite isolates to validate their blood products to date. Valley Biomedical has cultivated a donor pool that has been tailored to the needs of the difficult-to‐culture Plasmodium falciparum malaria parasite. This would include testing negative to CHAGAS, HBsAG, HBV‐ NAT, HIV ½, HCV, HCV‐NAT, HIV‐1 NAT, WNV, and Syphilis, and conforming to the FDA and all applicable Federal, State and Local regulations. This also includes screening donors for specific diet and medications that will not support the growth of the malaria parasite.

The North American Industry Classification System (NAICS) for this requirement is 325413 and the size standard is 1,250 Employees.

This announcement constitutes the only notice by the government; a written solicitation will not be issued. All sources that believe they are eligible to provide these items must respond in writing. Responses must be supported with clear and convincing evidence to clearly articulate the ability to provide the items outlined above. A request for documentation will not be considered an affirmative response. This Special Notice of Intent is not a request for competitive quotes. Information received will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no written responses are received by the date listed below, the purchase will be awarded without further remark. All questions and responses concerning this notice shall be emailed to Ms. Dawn Jennings at dawn.v.jennings.civ@mail.mil.

Interested concerns must identify their capability in writing to the above e-mail address or by mail to the address listed below no later than 3:00 pm EST, Thursday, February 7, 2019.

Contracting Office Address:
US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014

Point of Contact:
Dawn Jennings

.